| abstract |
The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof, which is a bitronectin receptor antagonist useful in the treatment of osteoporosis.n n n (I)n n n n n n n n In this formula,n n n A is a fibrinogen antagonist template;n n n W is - (CHR g ) a -U- (CHR g ) b -V- linked residues;n n n Q 1 , Q 2 , Q 3 and Q 4 are independently N or CR y with the proviso that only one of Q 1 , Q 2 , Q 3 and Q 4 is N;n n n R 'is H or C 1-6 alkyl, C 3-7 cycloalkyl, -C 0-6 alkyl or Ar-C 0-6 alkyl;n n n R g is H or C 1-6 alkyl, Het-C 0-6 alkyl, C 3-7 cycloalkyl, -C 0-6 alkyl or Ar-C 0-6 alkyl;n n n R k is R g , -C (O) R g, or -C (O) OR g ;n n n R i is H, C 1-6 alkyl, Het-C 0-6 alkyl, C 3-7 cycloalkyl, -C 0-6 alkyl, Ar-C 0-6 alkyl, Het-C 0-6 alkyl -U ' -C 1-6 alkyl, C 3-7 cycloalkyl-C 0-6 alkyl-U'-C 1-6 alkyl or Ar-C 0-6 alkyl-U'-C 1-6 alkyl;n n n R y is H, halo, -OR g , -SR g , -CN, -NR g R k , -NO 2 , -CF 3 , CF 3 S (O) r -, -CO 2 R g , -COR g Or -CONR g 2 or halo, -OR g , -SR g , -CN, -NR g R ", -NO 2 , -CF 3 , R'S (O) 3 -, -CO 2 R g , -COR g Or C 1-6 alkyl optionally substituted by -CONR g 2 ;n n n U and V is absent, or, CO, CR g 2, C (= CR g 2), S (O) c, O, NR g, CR g OR g, CR g (OR k) CR g 2, CR g 2 CR g (OR k), C (O) CR g 2, CR g 2 C (O), CONR i, NR i CO, OC (O), C (O) O, C (S) O, OC (S ), C (S) NR g , NR g C (S), S (O) 2 NR g, NR g S (O) 2 N = N, NR g NR g, NR g CR g 2, NR g CR g 2 , CR g 2 O, OCR g 2 , CR g = CR g , C≡C, Ar or Het;n n n a is 0, 1, 2 or 3;n n n b is 0, 1 or 2;n n n c is 0, 1 or 2;n n n r is 0, 1 or 2;n n n u is 0 or 1; |